Visual Abstract: Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer - For The Media

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 30, 2022

Media advisory: The full study is linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.2253?guestAccessKey=d809d096-4cd9-4e27-9c36-c802e22956bd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=063022

Visual Abstract

Authors: Ning Li, M.D., and Lingying Wu, M.D., of the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, are the corresponding authors.

(doi:10.1001/jamaoncol.2022.2253)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.